Multiple system atrophy: Current and future approaches to management

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 4, 2010, Pages 249-263

  Flabeau, Olivier ^a   Meissner, Wassilios G ^a   Tison, Franacois ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

multiple system atrophy; neurodegenerative diseases; neuroprotective agents; Parkinsonism; therapeutic

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; APOMORPHINE; BACLOFEN; BOTULINUM TOXIN A; BUSPIRONE; CLONAZEPAM; DESMOPRESSIN; DOMPERIDONE; EPHEDRINE; FLUDROCORTISONE; GABAPENTIN; IMMUNOGLOBULIN; LEVODOPA; LITHIUM; MACROGOL 3350; MIDODRINE; MINOCYCLINE; MOSAPRIDE CITRATE; OCTREOTIDE; PAPAVERINE; POLYCARBOPHIL; PROPRANOLOL; PROSTAGLANDIN E1; PYRIDOSTIGMINE; RASAGILINE; RECOMBINANT GROWTH HORMONE; RIFAMPICIN; THREO 3,4 DIHYDROXYPHENYLSERINE; UNINDEXED DRUG;

BRAIN DEPTH STIMULATION; BREATHING DISORDER; CEREBELLAR ATAXIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; ERECTILE DYSFUNCTION; EYE MOVEMENT DISORDER; HUMAN; HYPERSALIVATION; HYPERSEXUALITY; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSCILLOPSIA; PARKINSONISM; PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SHY DRAGER SYNDROME; SLEEP DISORDER; SPEECH THERAPY; SUDDEN DEATH; TRACHEOSTOMY; TRANSCRANIAL MAGNETIC STIMULATION; URINARY TRACT DISEASE; WATER INTOXICATION;

EID: 77954938514     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285610375328     Document Type: Review

References (170)

1. Anderson, K.N. and Shneerson, J.M. (2009) Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 5: 235-239.
2. Apostolidis, A., Dasgupta, P., Denys, P., Elneil, S., Fowler, C.J., Giannantoni, A. et al. (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55: 100-119.
3. Azher, S.N. and Jankovic, J. ( 2005) Camptocormia: pathogenesis, classification, and response to therapy. Neurology 65: 355-359.
4. Bannister, R., Gibson, W., Michaels, L. and Oppenheimer, D.R. ( 1981) Laryngeal abductor paralysis in multiple system atrophy. A report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. Brain 104: 351-368.
5. Beaulieu, J.M. and Caron, M.G. ( 2008) Looking at lithium: molecular moods and complex behaviour. Mol Interv 8: 230-241.
6. Bedlack, R.S., Maragakis, N. and Heiman-Patterson, T. ( 2008) Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. Proc Natl Acad Sci U S A 105: E17, author reply E18.
7. Benarroch, E.E. ( 2007) Brainstem respiratory control: substrates of respiratory failure of multiple system atrophy. Mov Disord 22: 155-161.
8. Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C. and Leigh, P.N. (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132: 156-171.
9. Bloch, F., Houeto, J.L., Tezenas du Montcel, S., Bonneville, F., Etchepare, F., Welter, M.L. et al. (2006) Parkinson's disease with camptocormia. J Neurol Neurosurg Psychiatry 77: 1223-1228.
10. Boesch, S.M., Wenning, G.K., Ransmayr, G. and Poewe, W. ( 2002) Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 72: 300-303.
11. Boeve, B.F., Silber, M.H. and Ferman, T.J. ( 2003) Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4: 281-284.
12. Brooks, D.J. and Seppi, K. (2009) Proposed neuro-imaging criteria for the diagnosis of multiple system atrophy. Mov Disord 24: 949-964.
13. Chen, H., Jacobs, E., Schwarzschild, M.A., McCullough, M.L., Calle, E.E., Thun, M.J. et al. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58: 963-967.
14. Chokroverty, S., Sharp, J.T. and Barron, K.D. ( 1978) Periodic respiration in erect posture in Shy-Drager syndrome. J Neurol Neurosurg Psychiatry 41: 980-986.
15. Colosimo, C., Albanese, A., Hughes, A.J., de Bruin, V.M. and Lees, A.J. ( 1995) Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 52: 294-298.
16. Constantinescu, R., Richard, I. and Kurlan, R. ( 2007) Levodopa responsiveness in disorders with Parkinsonism: a review of the literature. Mov Disord 22: 2141-2148, quiz 2295.
17. Constantinescu, R., Rosengren, L., Johnels, B., Zetterberg, H. and Holmberg, B. (2010) Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 16: 142-145.
18. Cormican, L.J., Higgins, S., Davidson, A.C., Howard, R. and Williams, A.J. ( 2004) Multiple system atrophy presenting as central sleep apnoea. Eur Respir J 24: 323-325.
19. de Seze, M.P., Creuze, A., de Seze, M. and Mazaux, J.M. ( 2008) An orthosis and physiotherapy programme for camptocormia: a prospective case study. J Rehabil Med 40: 761-765.
20. Deguchi, K., Ikeda, K., Sasaki, I., Shimamura, M., Urai, Y., Tsukaguchi, M. et al. (2007) Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy. J Neurol 254: 735-740.
21. Diederich, N.J., Goebel, H.H., Dooms, G., Bumb, A., Huber, F., Kompoliti, K. et al. (2006) Camptocormia associated with focal myositis in multiple-system atrophy. Mov Disord 21: 390-394.
22. Diguet, E., Fernagut, P.O., Scherfler, C., Wenning, G. and Tison, F. ( 2005) Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. J Neural Transm 112: 613-631.
23. Dodel, R., Spottke, A., Gerhard, A., Reuss, A., Reinecker, S., Schimke, N. et al. (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [ (11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25: 97-107.
24. Eichhorn, T.E. and Oertel, W.H. ( 2001) Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 16: 1176-1177.
25. Fearnley, J.M. and Lees, A.J. ( 1990) Striatonigral degeneration. A clinicopathological study. Brain 113: 1823-1842.
26. Feng, H.L., Leng, Y., Ma, C.H., Zhang, J., Ren, M. and Chuang, D.M. ( 2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155: 567-572.
27. Fernagut, P.O., Ghorayeb, I., Diguet, E. and Tison, F. ( 2005) In vivo models of multiple system atrophy. Mov Disord 20(Suppl 12): S57-S63.
28. Ferrucci, M., Spalloni, A., Bartalucci, A., Cantafora, E., Fulceri, F., Nutini, M. et al. (2010) A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol Dis 37: 370-383.
29. Fetoni, V., Soliveri, P., Monza, D., Testa, D. and Girotti, F. ( 1999) Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 66: 541-544.
30. Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M., Manca, M.L. et al. (2008) Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 105: 2052-2057.
31. Fowler, C.J. and O'Malley, K.J. ( 2003) Investigation and management of neurogenic bladder dysfunction. J Neurol Neurosurg Psychiatry 74(Suppl 4): iv27-iv31.
32. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R. et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344: 710-719.
33. Freeman, R. ( 2008) Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 358: 615-624.
34. Freeman, R., Landsberg, L. and Young, J. ( 1999) The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 53: 2151-2157.
35. Freeman, T.B., Olanow, C.W., Hauser, R.A., Nauert, G.M., Smith, D.A., Borlongan, C.V. et al. (1995) Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 38: 379-388.
36. Fregni, F., Santos, C.M., Myczkowski, M.L., Rigolino, R., Gallucci-Neto, J., Barbosa, E.R. et al. (2004) Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 75: 1171-1174.
37. Friess, E., Kuempfel, T., Modell, S., Winkelmann, J., Holsboer, F., Ising, M. et al. (2006) Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 12: 432-437.
38. Gaig, C., Iranzo, A., Tolosa, E., Vilaseca, I., Rey, M.J. and Santamaria, J. ( 2008) Pathological description of a non-motor variant of multiple system atrophy. J Neurol Neurosurg Psychiatry 79: 1399-1400.
39. Gazulla, J. and Benavente, M.I. ( 2005) [Improvements in the symptoms of olivopontocerebellar atrophy with gabapentin]. Rev Neurol 40: 285-288.
40. Gerton, B.K., Theeler, B. and Samii, A. (2010) Backpack treatment for camptocormia. Mov Disord 25: 247-248.
41. Geser, F., Seppi, K., Stampfer-Kountchev, M., Kollensperger, M., Diem, A., Ndayisaba, J.P. et al. (2005) The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 112: 1677-1686.
42. Ghorayeb, I., Bioulac, B. and Tison, F. ( 2005a) Sleep disorders in multiple system atrophy. J Neural Transm 112: 1669-1675.
43. Ghorayeb, I., Yekhlef, F., Bioulac, B. and Tison, F. ( 2005b) Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Med 6: 359-362.
44. Giannantoni, A., Rossi, A., Mearini, E., Del Zingaro, M., Porena, M. and Berardelli, A. (2009) Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 182: 1453-1457.
45. Gilman, S., May, S.J., Shults, C.W., Tanner, C.M., Kukull, W., Lee, V.M. et al. (2005) The North American Multiple System Atrophy Study Group. J Neural Transm 112: 1687-1694.
46. Gilman, S., Wenning, G.K., Low, P.A., Brooks, D.J., Mathias, C.J., Trojanowski, J.Q. et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670-676.
47. Glass, G.A., Josephs, K.A. and Ahlskog, J.E. ( 2006) Respiratory insufficiency as the primary presenting symptom of multiple-system atrophy. Arch Neurol 63: 978-981.
48. Hardy, J. ( 2008) Multiple system atrophy: pathophysiology, treatment and nursing care. Nurs Stand 22: 50-56, quiz 58.
49. Hauser, R.A., Freeman, T.B., Snow, B.J., Nauert, M., Gauger, L., Kordower, J.H. et al. (1999) Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56: 179-187.
50. Hayashi, M., Isozaki, E., Oda, M., Tanabe, H. and Kimura, J. ( 1997) Loss of large myelinated nerve fibres of the recurrent laryngeal nerve in patients with multiple system atrophy and vocal cord palsy. J Neurol Neurosurg Psychiatry 62: 234-238.
51. Heo, J.H., Lee, S.T., Chu, K. and Kim, M. ( 2008) The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 271: 87-90.
52. Hirohata, M., Ono, K., Morinaga, A. and Yamada, M. ( 2008) Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology 54: 620-627.
53. Hirsch, E.C. and Hunot, S. (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397.
54. Holmberg, B., Johansson, J.O., Poewe, W., Wenning, G., Quinn, N.P., Mathias, C. et al. (2007) Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 22: 1138-1144.
55. Hughes, A.J., Colosimo, C., Kleedorfer, B., Daniel, S.E. and Lees, A.J. ( 1992) The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 55: 1009-1013.
56. Hussain, I.F., Brady, C.M., Swinn, M.J., Mathias, C.J. and Fowler, C.J. ( 2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71: 371-374.
57. Iranzo, A. ( 2005) Management of sleep-disordered breathing in multiple system atrophy. Sleep Med 6: 297-300.
58. Iranzo, A., Santamaria, J. and Tolosa, E. ( 2000) Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet 356: 1329-1330.
59. Iranzo, A., Santamaria, J., Tolosa, E., Vilaseca, I., Valldeoriola, F., Marti, M.J. et al. (2004) Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 63: 930-932.
60. Ito, T., Sakakibara, R., Yasuda, K., Yamamoto, T., Uchiyama, T., Liu, Z. et al. (2006) Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 21: 816-823.
61. Jain, S., Dawson, J., Quinn, N.P. and Playford, E.D. ( 2004) Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 19: 1360-1364.
62. Jankovic, J., Gilden, J.L., Hiner, B.C., Kaufmann, H., Brown, D.C., Coghlan, C.H. et al. (1993) Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95: 38-48.
63. Jellinger, K.A. and Lantos, P.L. (2010) Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 119: 657-667.
64. Jin, K., Okabe, S., Chida, K., Abe, N., Kimpara, T., Ohnuma, A. et al. (2007) Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology 68: 1618-1621.
65. Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Spooren, W. et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3: 583-588.
66. Kaufmann, H. ( 2008) L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 18(Suppl 1): 19-24.
67. Kaufmann, H., Saadia, D., Voustianiouk, A., Goldstein, D.S., Holmes, C., Yahr, M.D. et al. (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108: 724-728.
68. Kawai, Y., Suenaga, M., Takeda, A., Ito, M., Watanabe, H., Tanaka, F. et al. (2008) Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 70: 1390-1396.
69. Kitayama, M., Wada-Isoe, K., Irizawa, Y. and Nakashima, K. (2009) Assessment of dementia in patients with multiple system atrophy. Eur J Neurol 16: 589-594.
70. Klos, K.J., Bower, J.H., Josephs, K.A., Matsumoto, J.Y. and Ahlskog, J.E. ( 2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11: 381-386.
71. Kollensperger, M., Geser, F., Seppi, K., Stampfer-Kountchev, M., Sawires, M., Scherfler, C. et al. (2008) Red flags for multiple system atrophy. Mov Disord 23: 1093-1099.
72. Kollensperger, M., Stefanova, N., Pallua, A., Puschban, Z., Dechant, G., Hainzer, M. et al. (2009) Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response. J Neurosci Res 87: 1679-1685.
73. Kollensperger, M. and Wenning, G.K. (2009) Assessing disease progression with MRI in atypical parkinsonian disorders. Mov Disord 24(Suppl 2): S699-S702.
74. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. and Olanow, C.W. ( 2008a) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14: 504-506.
75. Kordower, J.H., Chu, Y., Hauser, R.A., Olanow, C.W. and Freeman, T.B. ( 2008b) Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 23: 2303-2306.
76. Kordower, J.H., Freeman, T.B., Chen, E.Y., Mufson, E.J., Sanberg, P.R., Hauser, R.A. et al. (1998) Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 13: 383-393.
77. Lambrecq, V., Krim, E., Meissner, W., Guehl, D. and Tison, F. ( 2008) [Deep-brain stimulation of the internal pallidum in multiple system atrophy]. Rev Neurol (Paris) 164: 398-402.
78. Landers, M., Adams, M., Acosta, K. and Fox, A. (2009) Challenge-oriented gait and balance training in sporadic olivopontocerebellar atrophy: a case study. J Neurol Phys Ther 33: 160-168.
79. Lee, P.H., Kim, J.W., Bang, O.Y., Ahn, Y.H., Joo, I.S. and Huh, K. ( 2008) Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 83: 723-730.
80. Lindvall, O., Brundin, P., Widner, H., Rehncrona, S., Gustavii, B., Frackowiak, R. et al. (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247: 574-577.
81. Lindvall, O., Sawle, G., Widner, H., Rothwell, J.C., Bjorklund, A., Brooks, D. et al. (1994) Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35: 172-180.
82. Lipp, A., Sandroni, P., Ahlskog, J.E., Fealey, R.D., Kimpinski, K., Iodice, V. et al. (2009) Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 66: 742-750.
83. Liu, Z., Sakakibara, R., Odaka, T., Uchiyama, T., Yamamoto, T., Ito, T. et al. (2005) Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20: 680-686.
84. Low, P.A., Gilden, J.L., Freeman, R., Sheng, K.N. and McElligott, M.A. ( 1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277: 1046-1051.
85. Mancini, F., Zangaglia, R., Cristina, S., Sommaruga, M.G., Martignoni, E., Nappi, G. et al. (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in Parkinsonism. Mov Disord 18: 685-688.
86. Manni, R., Morini, R., Martignoni, E., Pacchetti, C., Micieli, G. and Tartara, A. ( 1993) Nocturnal sleep in multisystem atrophy with autonomic failure: poly-graphic findings in ten patients. J Neurol 240: 249-250.
87. Margraf, N.G., Wrede, A., Rohr, A., Schulz-Schaeffer, W.J., Raethjen, J., Eymess, A. et al. (2010) Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles. Mov Disord 25: 542-551.
88. Mathias, C.J. ( 2008) L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 18(Suppl 1): 25-29.
89. Mathias, C.J., Senard, J.M., Braune, S., Watson, L., Aragishi, A., Keeling, J.E. et al. (2001) L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 11: 235-242.
90. McClellan, K.J., Wiseman, L.R. and Wilde, M.I. ( 1998) Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 12: 76-86.
91. Meissner, W.G., Vital, A., Ghorayeb, I., Guehl, D. and Tison, F. ( 2010) Dyspnea as first sign of autonomic failure in postmortem confirmed multiple system atrophy. Mov Disord, in press.
92. Merlo, I.M., Occhini, A., Pacchetti, C. and Alfonsi, E. ( 2002) Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology 58: 649-652.
93. Mollenhauer, B. and Trenkwalder, C. (2009) Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 24: 1411-1426.
94. Nanri, K., Okita, M., Takeguchi, M., Taguchi, T., Ishiko, T., Saito, H. et al. (2009) Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 48: 783-790.
95. O'Sullivan, J.D. ( 2002) Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry 72: 681.
96. O'Sullivan, J.D. and Hughes, A.J. ( 1998) Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 13: 536-539.
97. Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.F. et al. (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54: 403-414.
98. Olanow, C.W., Gracies, J.M., Goetz, C.G., Stoessl, A.J., Freeman, T., Kordower, J.H. et al. (2009 a) Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord 24: 336-343.
99. Olanow, C.W., Rascol, O., Hauser, R., Feigin, P.D., Jankovic, J., Lang, A. et al. (2009 b) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268-1278.
100. Ono, K., Hirohata, M. and Yamada, M. ( 2007) Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. J Neurosci Res 85: 1547-1557.
101. Ono, K. and Yamada, M. ( 2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97: 105-115.
102. Osaki, Y., Ben-Shlomo, Y., Lees, A.J., Wenning, G.K. and Quinn, N.P. (2009) A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 24: 2272-2276.
103. Papapetropoulos, S., Tuchman, A., Sengun, C., Russell, A., Mitsi, G. and Singer, C. ( 2008) Anterocollis: clinical features and treatment options. Med Sci Monit 14: CR427-CR430.
104. Papatsoris, A.G., Papapetropoulos, S., Singer, C. and Deliveliotis, C. ( 2008) Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn 27: 22-27.
105. Pezzoli, G., Tesei, S., Canesi, M., Sacilotto, G., Vittorio, M., Mizuno, Y. et al. (2010) The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. Clin Neurol Neurosurg 112: 65-67.
106. Plazzi, G., Corsini, R., Provini, F., Pierangeli, G., Martinelli, P., Montagna, P. et al. (1997) REM sleep behavior disorders in multiple system atrophy. Neurology 48: 1094-1097.
107. Puschban, Z., Stefanova, N., Petersen, A., Winkler, C., Brundin, P., Poewe, W. et al. (2005) Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. Brain Res Bull 68: 54-58.
108. Quinn, N., Barker, R.A. and Wenning, G.K. ( 2008) Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Clin Pharmacol Ther 83: 663-665.
109. Rajput, A.H., Rozdilsky, B., Rajput, A. and Ang, L. ( 1990) Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 13: 553-558.
110. Ringman, J.M. and Simmons, J.H. ( 2000) Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 55: 870-871.
111. Sakakibara, R., Hattori, T., Uchiyama, T., Suenaga, T., Takahashi, H., Yamanishi, T. et al. (2000) Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 79: 191-195.
112. Sakakibara, R., Matsuda, S., Uchiyama, T., Yoshiyama, M., Yamanishi, T. and Hattori, T. ( 2003) The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 13: 106-108.
113. Sakakibara, R., Yamaguchi, T., Uchiyama, T., Yamamoto, T., Ito, T., Liu, Z. et al. (2007) Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 22: 1672-1673.
114. Samii, A., Etminan, M., Wiens, M.O. and Jafari, S. (2009) NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 26: 769-779.
115. Santens, P., Vonck, K., de Letter, M., van Driessche, K., Sieben, A., de Reuck, J. et al. (2006) Deep brain stimulation of the internal pallidum in multiple system atrophy. Parkinsonism Relat Disord 12: 181-183.
116. Schenck, C.H., Bundlie, S.R. and Mahowald, M.W. ( 1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46: 388-393.
117. Schrag, A., Ben-Shlomo, Y. and Quinn, N.P. ( 1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354: 1771-1775.
118. Schrag, A., Geser, F., Stampfer-Kountchev, M., Seppi, K., Sawires, M., Kollensperger, M. et al. (2006) Health-related quality of life in multiple system atrophy. Mov Disord 21: 809-815.
119. Schrag, A., Wenning, G.K., Quinn, N. and Ben-Shlomo, Y. ( 2008) Survival in multiple system atrophy. Mov Disord 23: 294-296.
120. Seppi, K., Peralta, C., Diem-Zangerl, A., Puschban, Z., Mueller, J., Poewe, W. et al. (2006) Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 13: 1146-1148.
121. Shih, L.C. and Tarsy, D. ( 2007) Deep brain stimulation for the treatment of atypical Parkinsonism. Mov Disord 22: 2149-2155.
122. Shimohata, T., Ozawa, T., Nakayama, H., Tomita, M., Shinoda, H. and Nishizawa, M. ( 2008) Frequency of nocturnal sudden death in patients with multiple system atrophy. J Neurol 255: 1483-1485.
123. Shimohata, T., Shinoda, H., Nakayama, H., Ozawa, T., Terajima, K., Yoshizawa, H. et al. (2007) Daytime hypoxemia, is sleep-disordered breathing, and laryngopharyngeal findings in multiple system atrophy. Arch Neurol 64: 856-861.
124. Shioda, K., Nisijima, K. and Kato, S. ( 2006) Electroconvulsive therapy for the treatment of multiple system atrophy with major depression. Gen Hosp Psychiatry 28: 81-83.
125. Shults, C.W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G. et al. (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25: 10689-10699.
126. Silber, M.H. ( 2008) Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology 70: 980, author reply 981-982.
127. Silber, M.H. and Levine, S. ( 2000) Stridor and death in multiple system atrophy. Mov Disord 15: 699-704.
128. Singer, W., Sandroni, P., Opfer-Gehrking, T.L., Suarez, G.A., Klein, C.M., Hines, S. et al. (2006) Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 63: 513-518.
129. Slawek, J., Derejko, M., Lass, P. and Dubaniewicz, M. ( 2006) Camptocormia or Pisa syndrome in multiple system atrophy. Clin Neurol Neurosurg 108: 699-704.
130. Song, I.U., Kim, J.S. and Lee, K.S. ( 2008) Dopa-responsive camptocormia in a patient with multiple system atrophy. Parkinsonism Relat Disord 14: 161-163.
131. Stefanova, N., Bucke, P., Duerr, S. and Wenning, G.K. (2009) Multiple system atrophy: an update. Lancet Neurol 8: 1172-1178.
132. Stefanova, N., Kollensperger, M., Hainzer, M., Cenci, A., Poewe, W. and Wenning, G.K. ( 2007) High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Mov Disord 22: 969-973.
133. Stefanova, N., Poewe, W. and Wenning, G.K. ( 2008) Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 210: 421-427.
134. Stefanova, N., Tison, F., Reindl, M., Poewe, W. and Wenning, G.K. ( 2005) Animal models of multiple system atrophy. Trends Neurosci 28: 501-506.
135. Suzuki, M., Saigusa, H., Shibasaki, K. and Kodera, K. (2010) Multiple system atrophy manifesting as complex sleep-disordered breathing. Auris Nasus Larynx 37: 110-113.
136. Tada, M., Kakita, A., Toyoshima, Y., Onodera, O., Ozawa, T., Morita, T. et al. (2009) Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain 132: 1810-1819.
137. Takei, A., Hamada, S., Homma, S., Hamada, K., Tashiro, K. and Hamada, T. (2009) Amelioration of subacute camptocormia in multiple system atrophy by protirelin tartrate. Mov Disord 24: 2022-2023.
138. Talmant, V., Esposito, P., Stilhart, B., Mohr, M. and Tranchant, C. ( 2006) [Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report]. Rev Neurol (Paris) 162: 363-370.
139. Tarsy, D., Apetauerova, D., Ryan, P. and Norregaard, T. ( 2003) Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy. Neurology 61: 247-249.
140. Tison, F., Wenning, G.K., Quinn, N.P. and Smith, S.J. ( 1995) REM sleep behaviour disorder as the presenting symptom of multiple system atrophy. J Neurol Neurosurg Psychiatry 58: 379-380.
141. Tison, F., Yekhlef, F. and Chrysostome, V. ( 2006) Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson's disease. Mov Disord 21: 1056-1057.
142. Tison, F., Yekhlef, F., Chrysostome, V., Balestre, E., Quinn, N.P., Poewe, W. et al. (2002) Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. Mov Disord 17: 701-709.
143. Tison, F., Yekhlef, F., Chrysostome, V. and Sourgen, C. ( 2000) Prevalence of multiple system atrophy. Lancet 355: 495-496.
144. Tsuda, T., Onodera, H., Okabe, S., Kikuchi, Y. and Itoyama, Y. ( 2002) Impaired chemosensitivity to hypoxia is a marker of multiple system atrophy. Ann Neurol 52: 367-371.
145. Ubhi, K., Rockenstein, E., Mante, M., Inglis, C., Adame, A., Patrick, C. et al. (2010) Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport, in press.
146. Ubhi, K., Rockenstein, E., Mante, M., Patrick, C., Adame, A., Thukral, M. et al. (2008) Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 19: 1271-1276.
147. Vanacore, N., Bonifati, V., Fabbrini, G., Colosimo, C., de Michele, G., Marconi, R. et al. (2001) Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 22: 97-99.
148. Vanacore, N. and Galeotti, F. ( 2008) A clinical specification for a randomized clinical trial on lithium in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 105: E35, author reply E36.
149. Venglar, M. ( 2005) Case report: Tai Chi and Parkinsonism. Physiother Res Int 10: 116-121.
150. Vetrugno, R., Liguori, R., Cortelli, P., Plazzi, G., Vicini, C., Campanini, A. et al. (2007) Sleep-related stridor due to dystonic vocal cord motion and neurogenic tachypnea / tachycardia in multiple system atrophy. Mov Disord 22: 673-678.
151. Vetrugno, R., Provini, F., Cortelli, P., Plazzi, G., Lotti, E.M., Pierangeli, G. et al. (2004) Sleep disorders in multiple system atrophy: a correlative video-polysomnographic study. Sleep Med 5: 21-30.
152. Visser-Vandewalle, V., Temel, Y., Colle, H. and van der Linden, C. ( 2003) Bilateral high-frequency stimulation of the subthalamic nucleus in patients with multiple system atrophy-Parkinsonism. Report of four cases. J Neurosurg 98: 882-887.
153. Watanabe, H., Saito, Y., Terao, S., Ando, T., Kachi, T., Mukai, E. et al. (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125: 1070-1083.
154. Waxman, E.A. and Giasson, B.I. (2010) A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem 113: 374-388.
155. Wedge, F. ( 2008) The impact of resistance training on balance and functional ability of a patient with multiple system atrophy. J Geriatr Phys Ther 31: 79-83.
156. Wenning, G.K. ( 2005) Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol 28: 225-227.
157. Wenning, G.K., Ben-Shlomo, Y., Hughes, A., Daniel, S.E., Lees, A. and Quinn, N.P. ( 2000) What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 68: 434-440.
158. Wenning, G.K., Ben-Shlomo, Y., Magalhaes, M., Daniel, S.E. and Quinn, N.P. ( 1995) Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 58: 160-166.
159. Wenning, G.K., Ben Shlomo, Y., Magalhaes, M., Daniel, S.E. and Quinn, N.P. ( 1994) Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 117: 835-845.
160. Wenning, G.K., Geser, F., Stampfer-Kountchev, M. and Tison, F. ( 2003) Multiple system atrophy: an update. Mov Disord 18(Suppl 6): S34-S42.
161. Wenning, G.K. and Stefanova, N. (2009) Recent developments in multiple system atrophy. J Neurol 256: 1791-1808.
162. Wenning, G.K., Stefanova, N., Jellinger, K.A., Poewe, W. and Schlossmacher, M.G. ( 2008) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64: 239-246.
163. Wenning, G.K., Tison, F., Ben Shlomo, Y., Daniel, S.E. and Quinn, N.P. ( 1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12: 133-147.
164. Wenning, G.K., Tison, F., Seppi, K., Sampaio, C., Diem, A., Yekhlef, F. et al. (2004) Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 19: 1391-1402.
165. Whone, A.L. and Scolding, N.J. ( 2009) Mesenchymal stem cells and neurodegenerative disease. Clin Pharmacol Ther 85: 19-20.
166. Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B. et al. (1992) Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327: 1556-1563.
167. Wright, R.A., Kaufmann, H.C., Perera, R., Opfer-Gehrking, T.L., McElligott, M.A., Sheng, K.N. et al. (1998) A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 51: 120-124.
168. Yamaguchi, M., Arai, K., Asahina, M. and Hattori, T. ( 2003) Laryngeal stridor in multiple system atrophy. Eur Neurol 49: 154-159.
169. Yazawa, I., Giasson, B.I., Sasaki, R., Zhang, B., Joyce, S., Uryu, K. et al. (2005) Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45: 847-859.
170. Young, T.M. and Mathias, C.J. ( 2004) The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry 75: 1737-1741.